Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death

Shan,Xiu; Tian,Li Li; Zhang,Yu  Mei; Wang,Xiao  Qi; Yan,Qiu; Liu,Ji  Wei

doi:10.3892/ijo.2015.3057

Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death

Authors:
- Xiu Shan
- Li Li Tian
- Yu Mei Zhang
- Xiao Qi Wang
- Qiu Yan
- Ji Wei Liu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Department of Dermatology, Northwestern University's Feinberg School of Medicine, Chicago, IL 60611, USA
Published online on: June 18, 2015 https://doi.org/10.3892/ijo.2015.3057
Pages: 701-709

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abnormal glycosylation is catalyzed by the specific glycosyltransferases and correlates with tumor cell apoptosis. Increased fucosyltransferase IV (FUT4) is seen in many types of cancer, and manipulating FUT4 expression through specific signaling pathway inhibits cell growth and induces apoptosis. NF-κB is known playing a vital role to control cell growth and apoptosis. Ginsenoside Rg3 is an herbal medicine with strong antitumor activity through inhibiting tumor growth and promoting tumor cell death. However, whether Rg3-induced inhibition on tumor development involves reduced NF-κB signaling and FUT4 expression remains unknown. In the present study, we found that Rg3 suppressed FUT4 expression by abrogating the binding of NF-κB to FUT4 promoter through inhibiting the expression of signaling molecules of NF-κB pathway, reducing NF-κB DNA binding activity and NF-κB transcription activity. NF-κB inhibitor (Bay 11-7082) or knocking down p65 expression by p65 siRNA also led to a significant decreased FUT4 expression. In addition, Rg3 induced apoptosis by activating both extrinsic and intrinsic apoptotic pathways. Moreover, in a xenograft mouse model, Rg3 downregulated FUT4 and NF-κB/p65 expression and suppressed melanoma cell growth and induced apoptosis without any noticeable toxicity. In conclusion, Rg3 induces tumor cell apoptosis correlated with its inhibitory effect on NF-κB signaling pathway-mediated FUT4 expression. Results suggest Rg3 might be a novel therapy agent for melanoma treatment.

View Figures

View References

1	McGettigan S: Dabrafenib: A new therapy for use in BRAF-mutated metastatic melanoma. J Adv Pract Oncol. 5:211–215. 2014.PubMed/NCBI
2	Lens MB and Dawes M: Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 150:179–185. 2004. View Article : Google Scholar : PubMed/NCBI
3	Rigel DS, Russak J and Friedman R: The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin. 60:301–316. 2010. View Article : Google Scholar
4	Menaa F: Latest approved therapies for metastatic melanoma: What comes next? J Skin Cancer. 2013:7352822013. View Article : Google Scholar : PubMed/NCBI
5	Graham B and Gibson SB: The two faces of NFkappaB in cell survival responses. Cell Cycle. 4:1342–1345. 2005. View Article : Google Scholar : PubMed/NCBI
6	Kiernan R, Brès V, Ng RWM, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S and Benkirane M: Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem. 278:2758–2766. 2003. View Article : Google Scholar
7	Doyle SL and O’Neill LA: Toll-like receptors: From the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol. 72:1102–1113. 2006. View Article : Google Scholar : PubMed/NCBI
8	Perkins ND and Gilmore TD: Good cop, bad cop: The different faces of NF-kappaB. Cell Death Differ. 13:759–772. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kashani-Sabet M, Liu Y, Fong S, Desprez PY, Liu S, Tu G, Nosrati M, Handumrongkul C, Liggitt D, Thor AD, et al: Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci USA. 99:3878–3883. 2002. View Article : Google Scholar : PubMed/NCBI
10	Kashani-Sabet M, Shaikh L, Miller JR III, Nosrati M, Ferreira CM, Debs RJ and Sagebiel RW: NF-kappa B in the vascular progression of melanoma. J Clin Oncol. 22:617–623. 2004. View Article : Google Scholar : PubMed/NCBI
11	Munshi A, Kurland JF, Nishikawa T, Chiao PJ, Andreeff M and Meyn RE: Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol Cancer Ther. 3:985–992. 2004.PubMed/NCBI
12	Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG and Aggarwal BB: Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther. 5:1434–1445. 2006. View Article : Google Scholar : PubMed/NCBI
13	Fuster MM and Esko JD and Esko JD: The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat Rev Cancer. 5:526–542. 2005. View Article : Google Scholar : PubMed/NCBI
14	Weston BW, Nair RP, Larsen RD and Lowe JB: Isolation of a novel human alpha (1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha (1,3/1,4) fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specificities. J Biol Chem. 267:4152–4160. 1992.PubMed/NCBI
15	Weston BW, Smith PL, Kelly RJ and Lowe JB: Molecular cloning of a fourth member of a human alpha (1,3)fucosyltransferase gene family. Multiple homologous sequences that determine expression of the Lewis x, sialyl Lewis x, and difucosyl sialyl Lewis x epitopes. J Biol Chem. 267:24575–24584. 1992.PubMed/NCBI
16	Petretti T, Schulze B, Schlag PM and Kemmner W: Altered mRNA expression of glycosyltransferases in human gastric carcinomas. Biochim Biophys Acta. 1428:209–218. 1999. View Article : Google Scholar : PubMed/NCBI
17	Ito H, Hiraiwa N, Sawada-Kasugai M, Akamatsu S, Tachikawa T, Kasai Y, Akiyama S, Ito K, Takagi H and Kannagi R: Altered mRNA expression of specific molecular species of fucosyl- and sialyl-transferases in human colorectal cancer tissues. Int J Cancer. 71:556–564. 1997. View Article : Google Scholar : PubMed/NCBI
18	Ogawa J, Inoue H and Koide S: Expression of alpha-1,3-fucosyltransferase type IV and VII genes is related to poor prognosis in lung cancer. Cancer Res. 56:325–329. 1996.PubMed/NCBI
19	Yang X, Zhang Z, Jia S, Liu Y, Wang X and Yan Q: Overexpression of fucosyltransferase IV in A431 cell line increases cell proliferation. Int J Biochem Cell Biol. 39:1722–1730. 2007. View Article : Google Scholar : PubMed/NCBI
20	Yang X, Liu S and Yan Q: Role of fucosyltransferase IV in epithelial-mesenchymal transition in breast cancer cells. Cell Death Dis. 4:e7352013. View Article : Google Scholar : PubMed/NCBI
21	Yang X, Liu Y, Liu J, Wang X and Yan Q: Cyclophosphamide-induced apoptosis in A431 cells is inhibited by fucosyltransferase IV. J Cell Biochem. 112:1376–1383. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yuan HD, Quan HY, Zhang Y, Kim SH and Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep. 3:825–831. 2010.
23	Park EH, Kim YJ, Yamabe N, Park SH, Kim HK, Jang HJ, Kim JH, Cheon GJ, Ham J and Kang KS: Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J Ginseng Res. 38:22–27. 2014. View Article : Google Scholar : PubMed/NCBI
24	Kim SM, Lee SY, Cho JS, Son SM, Choi SS, Yun YP, Yoo HS, Yoon Y, Oh KW, Han SB, et al: Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol. 631:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
25	Lee CK, Park KK, Chung AS and Chung WY: Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxido-reductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem Toxicol. 50:2565–2574. 2012. View Article : Google Scholar : PubMed/NCBI
26	Yu Y, Zhang C, Liu L and Li X: Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas. Exp Ther Med. 5:761–766. 2013.PubMed/NCBI
27	Shan X, Aziz F, Tian LL, Wang XQ, Yan Q and Liu JW: Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression. Int J Oncol. 46:1667–1676. 2015.PubMed/NCBI
28	Wang JH, Nao JF, Zhang M and He P: 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol. 35:11985–11994. 2014. View Article : Google Scholar : PubMed/NCBI
29	Kim BM, Kim DH, Park JH, Surh YJ and Na HK: Ginsenoside Rg3 inhibits constitutive activation of NF-κB signaling in human breast cancer (MDA-MB-231) cells: ERK and Akt as potential upstream targets. J Cancer Prev. 19:23–30. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zhang Z, Sun P, Liu J, Fu L, Yan J, Liu Y, Yu L, Wang X and Yan Q: Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta. 1783:287–296. 2008. View Article : Google Scholar
31	Yang X, Wang J, Liu S and Yan Q: HSF1 and Sp1 regulate FUT4 gene expression and cell proliferation in breast cancer cells. J Cell Biochem. 115:168–178. 2014. View Article : Google Scholar
32	Hongyan L, Shaoming T and Qiu Y: Correlation between FUT4 expression and its promoter methylation in HaCaT cells. Yi Chuan. 37:48–54. 2015.PubMed/NCBI
33	Kim MK, Jeon YK, Woo JK, Choi Y, Choi DH, Kim YH and Kim CW: The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1. Mol Cancer. 10:982011. View Article : Google Scholar
34	Brandi G, Pantaleo MA, Biasco G and Paterini P: Activated NF-κB in colorectal cancer: Predictive or prognostic factor? J Clin Oncol. 26:1388–1389; author reply 1389–1390. 2008. View Article : Google Scholar
35	Richmond A: NF-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2:664–674. 2002. View Article : Google Scholar : PubMed/NCBI
36	Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer. 2:301–310. 2002. View Article : Google Scholar : PubMed/NCBI
37	Melnikova VO and Bar-Eli M: Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther. 7:997–1003. 2008. View Article : Google Scholar : PubMed/NCBI
38	Heon Seo K, Ko HM, Kim HA, Choi JH, Jun Park S, Kim KJ, Lee HK and Im SY: Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappaB activation. Cancer Res. 66:4681–4686. 2006. View Article : Google Scholar : PubMed/NCBI
39	Cheng L, Luo S, Jin C, Ma H, Zhou H and Jia L: FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI